Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial [PDF]
British Journal of Cancer, 2002 This randomised, double-blind, placebo-controlled study was designed to evaluate the ability of the orally administered matrix metalloproteinase inhibitor, marimastat, to prolong survival in patients with non-resectable gastric and gastro-oesophageal adenocarcinoma.
Simon R. Bramhall +11 more
semanticscholar +4 more sources
Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen [PDF]
British Journal of Cancer, 1999 Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot, escalating-dose study of oral marimastat was performed in patients with recurrent colorectal cancer, in whom evaluation of serological response was made by measurement of carcinoembryonic antigen (CEA) levels.
John Primrose +12 more
semanticscholar +5 more sources
Inside a Metastatic Fracture: Molecular Bases and New Potential Therapeutic Targets [PDF]
Cancer MedicineIntroduction Bone metastases and pathological fractures significantly impact the prognosis and quality of life in cancer patients. However, clinical and radiological features alone have been shown to fail to predict skeletal related events of a bone ...
Alessandro Bruschi +10 more
doaj +3 more sources
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer [PDF]
British Journal of Cancer, 2004 Marimastat, low molecular weight heparins and captopril have antiangiogenic activity in vitro and in animal models. We studied the safety and efficacy of the combination of these drugs in patients with advanced cancer. In all, 50 patients were enrolled. Captopril was given orally at a dose of 50 mg bd daily.
Philip H. Jones +12 more
semanticscholar +4 more sources
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer [PDF]
Annals of Oncology, 2002 This pilot trial was performed to evaluate the safety, toxicity and pharmacokinetics of chronic therapy with the matrix metalloproteinase inhibitor marimastat in the adjuvant treatment of breast cancer.Patients with high-risk node negative or node positive breast cancer received marimastat either 5 or 10 mg p.o. b.i.d. for 12 months.
Kathy D. Miller +7 more
semanticscholar +4 more sources
In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol
ToxiconAnandie le Roux +3 more
semanticscholar +3 more sources
In vivo Efficacy of Marimastat and Chemoradiation in Head and Neck Cancer Xenografts [PDF]
ORL, 2008 <i>Objective:</i> To assess the effect of combining a synthetic matrix metalloprotease inhibitor and chemoradiation therapy on tumor growth in a murine model of head and neck squamous-cell carcinoma (SCC). <i>Methods:</i> Athymic, nude mice bearing SCC-1 xenografts were used to comprise 4 treatment groups: (1) control receiving ...
Joni B. Skipper +4 more
openalex +3 more sources
Preclinical evaluation of small molecule inhibitors as early intervention therapeutics against Russell’s viper envenoming in India [PDF]
Communications MedicineBackground Snakebites are problematic in many developing regions, including India, where over half of global snakebite deaths occur. Antivenoms are currently the only licensed treatment for snakebites.
Gotravalli V. Rudresha +3 more
doaj +2 more sources
The EGFR Signaling Pathway Is Involved in the Biliary Intraepithelial Neoplasia Associated with Liver Fluke Infection [PDF]
PathogensFoodborne trematode infections are recognized as a significant risk factor for cholangiocarcinoma (CCA) in endemic regions. Infection with the liver fluke Opisthorchis felineus induces precursor lesions of CCA, including the biliary intraepithelial ...
Dmitry Ponomarev +5 more
doaj +2 more sources
ASSESSING TARGET SPECIFICITY OF THE SMALL MOLECULE INHIBITOR MARIMASTAT TO SNAKE VENOM TOXINS: A NOVEL APPLICATION OF THERMAL PROTEOME PROFILING [PDF]
bioRxiv, 2023 New treatments that circumvent the pitfalls of traditional antivenom therapies are critical to address the problem of snakebite globally. Numerous snake venom toxin inhibitors have shown promising cross-species neutralization of medically significant ...
Cara F. Smith +15 more
openalex +2 more sources